Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03872453 · ClinicalTrials.gov registry record · Phase 2
Acute Treatment Trial in Adult Subjects With Migraines
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 2,154
- Enrollment target
NCT03872453 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 2,154 participants.
The verdict
NCT03872453, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2,154 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and efficacy of three different intranasal dose levels of zavegepant (BHV-3500), relative to placebo, in the acute treatment of moderate to severe migraine.
Interventions
- DRUG Zavegepant
- DRUG Zavegepant matching placebo
- DEVICE Intranasal Aptar Pharma Unit Dose System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,154 participants |
| Start Date | 2019-03-25 |
| Est. Completion | 2019-11-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03872453
The ClinicalTrials.gov registry entry for NCT03872453 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2,154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Zavegepant is the first listed.
NCT03872453 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03872453 about?
NCT03872453 is a clinical study titled "Acute Treatment Trial in Adult Subjects With Migraines". The purpose of the study is to evaluate the safety and efficacy of three different intranasal dose levels of zavegepant (BHV-3500), relative to placebo, in the acute treatment of moderate to severe migraine.
What is the current status of trial NCT03872453?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2,154 participants. The study started on 2019-03-25. Estimated completion is 2019-11-11.
What interventions are being tested in trial NCT03872453?
The interventions under investigation include: Zavegepant (DRUG), Zavegepant matching placebo (DRUG), Intranasal Aptar Pharma Unit Dose System (DEVICE).
Who is sponsoring clinical trial NCT03872453?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.